Search Medical Condition
Please enter condition
Please choose location from dropdown

Xuzhou, China Clinical Trials

A listing of Xuzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (67) clinical trials

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. The operation indication includes non-absorbed vitreous haemorrhage, dense bleeding in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal detachment combined break, severe progressive fiber vascular proliferation and vitreous haemorrhage combined with early iris neovascularization. Due ...

Phase

8.9 miles

Learn More »

Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

Phase

8.9 miles

Learn More »

A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms

This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in patients with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two cohorts of patients: Cohort 1: Patients with relapsed or refractory extranodal NK/T cell lymphoma ...

Phase

8.9 miles

Learn More »

25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. The operation indication includes non-absorbed vitreous haemorrhage, dense bleeding in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal detachment combined break, severe progressive fiber vascular proliferation and vitreous haemorrhage combined with early iris neovascularization. Due ...

Phase

8.9 miles

Learn More »

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Phase

8.9 miles

Learn More »

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases

This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced NSCLC with CNS metastases. Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-nave advanced NSCLC and documented intracranial disease ...

Phase

8.9 miles

Learn More »

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

The total duration of study per patient is approximately 40 weeks, including 4 to 5 weeks of screening period, 24 weeks of treatment period and 12 weeks of post-treatment period.

Phase

8.9 miles

Learn More »